Novartis Fabhalta® improved paroxysmal nocturnal hemoglobinuria in Phase 3

 Novartis today announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switched from anti-C5 therapies (Hb ≥10g/dL following treatment with eculizumab or ravulizumab)1. After 24 weeks of treatment with Fabhalta, the average Hb level improved versus baseline

https://finance.yahoo.com/news/phase-iiib-data-shows-novartis-061500669.html